At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Pembrolizumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-Arm, Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, Quality-of-Life Assessment, and 2 other interventions for Lung Non-Small Cell Carcinoma and 8 related conditions. Completed, enrolled 45 participants across 2 sites.
Detailed Summary
This phase II trial studies how well pembrolizumab works in preventing lung cancer patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartNov 2018
Primary CompletionJan 2026
Study CompletionMar 2026
TodayJul 2026
First PostedAug 16, 2018
Enrollment StartNov 13, 2018
Primary CompletionJan 27, 2026
Study CompletionMar 11, 2026
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 7.9 years ago
Interventions
Pembrolizumabbiological
Given IV
Quality-of-Life Assessmentother
Ancillary studies
Computed Tomographyprocedure
Undergo CT
Biospecimen Collectionprocedure
Undergo collection of blood samples